(Sharecast News) - Avacta reported new pharmacology data on its second oncology asset, FAP-Exd (AVA6103), on Thursday, showing sustained tumor exposure and prolonged responses across multiple preclinical models, as the company prepared to begin phase one testing in the first quarter of 2026.
The AIM-traded clinical-stage biopharmaceutical group said the data...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE